Top

25-07-2017 | Gastric cancer | Article

The Effect of Neoadjuvant Chemoradiation on Anastomotic Leak and Additional 30-Day Morbidity and Mortality in Patients Undergoing Total Gastrectomy for Gastric Cancer

Journal: Journal of Gastrointestinal Surgery

Authors: Ivy N. Haskins, Matthew D. Kroh, Richard L. Amdur, Jeffrey L. Ponksy, John H. Rodriguez, Khashayar Vaziri

Abstract

Introduction

In addition to increased perioperative morbidity, anastomotic leak following gastric resection for gastric cancer can have detrimental effects on overall and disease-free survival. The risk of anastomotic leak following neoadjuvant therapy remains unknown. The purpose of this study is to investigate the association of preoperative chemotherapy and radiation therapy with postoperative anastomotic leak and additional 30-day morbidity and mortality outcomes following total gastrectomy with reconstruction for gastric cancer using the American College of Surgeons National Surgical Quality Improvement Program (ACS-NSQIP).

Methods

Patients who underwent total gastrectomy with reconstruction for gastric cancer from 2005 to 2012 were identified. Within the NSQIP database, anastomotic leak is captured as an organ space infection. The association of preoperative chemotherapy and radiation therapy with anastomotic leak and additional 30-day morbidity and mortality outcomes was investigated using chi-squared analysis, Fisher’s exact test, and Student’s t test.

Results

A total of 1135 patients met inclusion criteria; 121 (10.7%) patients underwent preoperative chemotherapy within 30 days of surgery, and 53 (4.7%) patients underwent preoperative radiation therapy within 90 days of surgery. Neither preoperative chemotherapy nor radiation therapy was associated with an increased risk of anastomotic leak (p = 0.12 and p = 0.58, respectively). When compared to patients who did not undergo neoadjuvant therapy, patients who underwent either preoperative chemotherapy or radiation therapy did not experience a higher frequency of 30-day mortality (p = 0.41), cardiac (p = 0.49), wound (p = 0.76), renal (p = 0.13), septic (p = 0.55), or venous thromboembolism (p = 0.19) events and were significantly less likely to experience a pulmonary event (p = 0.02).

Conclusion

Neoadjuvant therapy prior to gastric resection for gastric cancer is not associated with an increased risk of anastomotic leak or other additional short-term morbidity or mortality.

Kim SH, Son SY, Park YS, Ahn SH, Park DJ, Kim HH (2015) Risk Factors for Anastomotic Leakage: A Retrospective Cohort Study in a Single Gastric Surgical Unit. J Gastric Cancer 15.3: 167–175.CrossRefPubMedPubMedCentral

Snyder RA, Penson DF, Koyama T, Merchant NB (2014) Trends in the Use of Evidence-Based Therapy for Resectable Gastric Cancer. J Surg Oncol 110.3: 285–290.CrossRefPubMedPubMedCentral

Datta J, McMillan MT, Shang EK, Mamtani R, Lewis RS, Kelz RR, Teitelbaum U, Plastaras JP, Drebin JA, Fraker DL, Karakousis GC, Roses RE (2015) Omission of Adjuvant Therapy after Gastric Cancer Resection: Development of a Validated Risk Model. J Natl Compr Canc Netw 13.5: 531–541.CrossRefPubMed

SEER Stat Fact Sheets: Stomach Cancer. National Cancer Institute. Bethesda, MD. http://seer.cancer.gov/statfacts/html/stomach.html. Accessed November 10, 2016.

MacDonald JS, Smalley SR, Benedetti J, Hundahl SA, Estes NC, Stemmermann GN, Haller DG, Ajani JA, Gunderson LL, Jessup JM, Martenson JA (2001) Chemoradiotherapy after Surgery Compared with Surgery Alone for Adenocarcinoma of the Stomach or Gastroesophageal Junction. N Engl J Med 345.5: 725–730.CrossRefPubMed

Zhang ZX, Gu XZ, Tin WB, Huang GJ, Zhang DW, Zhang RG (1998) Randomized Clinical Trial on the Combination of Preoperative Irradiation and Surgery in the Treatment of Adenocarcinoma of Gastric Cardia (GC)—Report on 370 Patients. Int J Radiation Oncology Biol Phys 42.5: 929–934.CrossRef

Ychou M, Boige V, Pignon JP, Conroy T, Bouche O, Lebreton G, Ducourtieux M, Bedenne L, Fabre JM, Saint-Aubert B, Geneve J, Lasser P, Rougier P. Perioperative Chemotherapy Compared with Surgery Alone for Resectable Gastroesophageal Adenocarcinoma: An FNCLCC and FFCD Multicenter Phase III Trial (2011) J Clin Oncol 29.13: 1715–1721.CrossRefPubMed

Skoropad VY, Berdov BA, Mardynski YS, Titova LV. A Prospective, Randomized Trial of Pre-Operative and Intraoperative Radiotherapy versus Surgery Alone in Resectable Gastric Cancer (2000) Eur J Surg Oncol 26: 773–779.CrossRefPubMed

Choi AH, Kim J, Chao J. Perioperative Chemotherapy for Resectable Gastric Cancer: MAGIC and Beyond (2015) World J Gastroenterol 21.24: 7343–7348.CrossRefPubMedPubMedCentral

10.

Stahl M, Walz MK, Stuschke M, Lehmann N, Meyer HJ, Riera-Knorrenschild J, Langer P, Engenhart-Cabillic R, Bitzer M, Konigsrainer A, Buddach W, Wilke H. Phase III Comparison of Preoperative Chemotherapy Compared with Chemoradiotherapy in Patients with Locally Advanced Adenocarcinoma of the Esophagogastric Junction (2009) J Clin Oncol 27: 851–856.CrossRefPubMed

11.

Cunningham D, Allum WH, Stenning SP, Thompson JN, Van de Velde CJH, Nicolson M, Scarffe H, Lofts FJ, Falk SJ, Iveson TJ, Smither DB, Langley RE, Verma M, Weedne S, Chua YJ. Perioperative Chemotherapy versus Surgery Along for Resectable Gastroesophageal Cancer. N Engl J Med. 2006; 355.1: 11–20.CrossRefPubMed

12.

Sierzga M, Kolodziejczyk P, Kulig J, Polish Gastric Cancer Study Group (2010) Br J Surg 97.7: 1035–1042.CrossRef

13.

ACS NSQIP Participant Use Data File. https://www.facs.org/quality-programs/acs-nsqip/program-specifics/participant-use. Accessed November 10, 2016.

14.

Deguchi Y, Fukagawa T, Morita S, Ohashi M, Saka M, Katai H. Identification of Risk Factors for Esophagojejunal Anastomotic Leakage after Gastric Surgery (2012) World J Surg 36: 1617–1622.CrossRefPubMed

15.

Kang YK, Yook JH, Chang HM, Ryu MH, Yoo C, Zang DY, Lee JL, Kim TW, Yang DH, Jang SJ, Park YS, Lee YJ, Jung HY, Kim JH, Kim BS. Enhanced Efficacy of Postoperative Adjuvant Chemotherapy in Advanced Gastric Cancer: Results from a Phase 3 Randomized Trial (AMC0101) (2014) Cancer Chemother Pharmacol 73.1: 139–149.CrossRefPubMed

16.

Chang HM, Jung KH, Kim TY, Kim WS, Yang HK, Lee KU, Choe KJ, Heo DS, Bang YJ, Kim NK. A Phase III Randomized Trial of 5-Fluorouracil, Doxorubicin, and Mitomycin C versus 5-Fluorouracil and Mitomycin C versus 5-Fluorouracil Alone in Curatively Resected Gastric Cancer (2012) Ann Oncol 13.11: 1799–1785.

17.

Koo DH, Lee JL, Kim TW, Chang HW, Ryu MH, Yook JH, Oh ST, Kim BS, Lee JS, Kang YK. Adjuvant Chemotherapy with 5-Fluorouracil, Doxorubicin, and Mitomycin-C (FAM) for 6 Months after Curative Resection of Gastric Carcinoma (2007) Eur J Surg Oncol 33.7: 843–848.CrossRefPubMed

18.

Fischer C, Lingsma H, Hardwick R, Cromwell DA, Steyerberg E, Groene O. Risk Adjustment Models for Short-Term Outcomes after Surgical Resection for Oesophagogatric Cancer (2016) Br J Surg 103.1: 105–116.CrossRefPubMed

19.

Lo CH, Chen JH, Wu CW, Lo SS, Hsieh MC, Lui WY. Risk Factors and Management of Intra-Abdominal Infection after Extended Radical Gastrectomy (2008) Am J Surg 196.5: 741–745.CrossRefPubMed

20.

Kodera Y, Sasako M, Yamamoto S, Sano T, Nashimoto A, Kurita A. Identification of Risk Factors for the Development of Complications following Extended and Superextended Lymphadenectomies for Gastric Cancer (2005) Br J Surg 92.9: 1103–1109.CrossRefPubMed

21.

Hartgrink HH, Van de Helde CJH, Nonenkamp JJ, Kranenbarg EK, Songun I, Welvaart K, van Krieken JHJM, Meijer S, Plukker JTM, van Elk PJ, Obertop J, Gouma DJ, van Lanschot JJB, Taat CW, de Graff PW, von Meyenfeldt MF, Tilanus H, Sasako M. Extended Lymph Node Dissection for Gastric Cancer: Who May Benefit? Final Results of the Randomized Dutch Gastric Cancer Group Trial (2004) J Clin Oncol 22.11: 2069–2077.CrossRefPubMed

22.

Lee HH, Son SY, Lee JH, et al. Surgeon’s Experience Overrides the Effect of Hospital Volume for Postoperative Outcomes of Laparoscopic Surgery in Gastric Cancer: Multi-Institutional Study, DOI: 10.1245/s10434-016-5672-7, November 10, 2016.

23.

Wong RKS, Jang R, and Darling G. Postoperative Chemoradiotherapy vs. Preoperative Chemoradiotherapy for Locally Advanced (Operable) Gastric Cancer: Clarifying the Role and Technique of Radiotherapy. J Gastrointest Oncol. 2015; 6.1: 89–107.PubMedPubMedCentral

24.

Haskins IN, Amdur R, Vaziri K. The Effect of Smoking on Bariatric Surgical Outcomes (2014) Surg Endosc 28.11: 3074–3080.CrossRefPubMed

25.

Massomi H, Reavis K, Smith BR, Kim H, Stamos MJ, Nguyen NT. Risk Factors for Acute Respiratory Failure in Bariatric Surgery: Data from the Nationwide Inpatient Sample (2013) Surg Obes Relat Dis 9.2: 277–281.CrossRef

26.

Miki Y, Makuuchi R, Tokunaga M, Tanizawa Y, Bando E, Kawamura T, Terashima M. Risk Factors for Postoperative Pneumonia after Gastrectomy for Gastric Cancer (2016) Surg Today 46.5: 552–556.CrossRefPubMed